Since 1995, Reliable Business Intelligence for Clinical Laboratories, Pathology Groups and Laboratory Diagnostics

Search

TDR Insider

Might Lawsuits Come Next in the Theranos Story?

Tailored to the needs and interests of lab administrators and pathologists, THE DARK REPORT provides new insights into the continuing saga of Theranos. A stream of headline stories in recent weeks has painted the controversial lab testing company in an uncomplimentary way, and TDR puts you front and center in these important developments. Have you been […]

To access this post, you must purchase The Dark Report.

Might Lawsuits Come Next in the Theranos Story? Read More »

Lab Professionals Long Knew of Challenges at Theranos

CEO SUMMARY: As THE DARK REPORT has continually reported, pathologists and medical laboratory professionals in the San Francisco and Phoenix markets were aware for most of the past year that Theranos was not delivering to patients and consumers the specific lab testing services it regularly touted in news stories and at conferences. Another sign was that,

To access this post, you must purchase The Dark Report.

Lab Professionals Long Knew of Challenges at Theranos Read More »

Protecting Access to Medicare Act of 2014: Will price reporting rule drive small labs out of business?

This first assessment of the PAMA (Protecting Access to Medicare Act of 2014) proposed rule on market reporting of lab prices gives pathologists and lab executives insights about the good, the bad, and the ugly in the language of the proposed rule. One lab group representing independent and community lab companies says that the proposed

To access this post, you must purchase The Dark Report.

Protecting Access to Medicare Act of 2014: Will price reporting rule drive small labs out of business? Read More »

New Developments in $1 Billion Laboratory Fraud Case

IT’S THE $1 BILLION LABORATORY FRAUD that no one realized had grown so big. In this special issue of THE DARK REPORT, you’ll read how the next chapter of the federal whistleblower lawsuit against three specialty cardiology labs and certain individuals has pulled the curtain open on what we believe is the biggest case of laboratory fraud and abuse in the past 30 years. Court documents

To access this post, you must purchase The Dark Report.

New Developments in $1 Billion Laboratory Fraud Case Read More »

Is New Cycle of Laboratory Fraud Plaguing the Industry?

CEO SUMMARY: Taken collectively, the growing number of federal investigations of lab companies and health insurer lawsuits against lab companies alleging fraudulent business practices signals a disturbing new trend for the lab industry.  In THE DARK REPORT’s typical hard-hitting analysis of an emerging clinical laboratory trend, it is noted that while these allegations are leveled at just a handful of

To access this post, you must purchase The Dark Report.

Is New Cycle of Laboratory Fraud Plaguing the Industry? Read More »

New company ready to heat up slow digital pathology market

IN THE 2000S, DIGITAL PATHOLOGY WAS THE HOT NEW TECHNOLOGY that held great potential to transform anatomic pathology in myriad ways, not the least of which was an essential tool to streamline pathologist workflow while supporting greater diagnostic precision. Yet today, approximately 10 years later, those high hopes for the digital pathology market have not

To access this post, you must purchase The Dark Report.

New company ready to heat up slow digital pathology market Read More »

Combining Lean Techniques with Lab Automation to Get Impressive Results

PROBABLY NO AREA OF CLINICAL LABORATORY MEDICINE is experiencing the dramatic transformation happening in microbiology. From rapid molecular testing to the full automation of traditional manual processes, significant changes are happening in microbiology labs. Moreover, the smart use of Lean techniques and quality management techniques magnify the positive effects of these new diagnostic technologies and

To access this post, you must purchase The Dark Report.

Combining Lean Techniques with Lab Automation to Get Impressive Results Read More »

Medicare Ends Coverage for Some Pharmacogenomic Testing

CEO SUMMARY: Medicare’s decision to cease covering many pharmacogenomic tests puts as many as 19 million Americans who have genetic variations affecting their response to medications at risk. These medications are commonly prescribed for patients with cardiovascular disease, pain, depression, anxiety, and cancer. Meanwhile, medical centers such as Mayo Clinic are conducting clinical studies to collect evidence that appropriate use of pharmacogenomic tests can improve patient outcomes while also reducing the cost of care.

To access this post, you must purchase The Dark Report.

Medicare Ends Coverage for Some Pharmacogenomic Testing Read More »

Some Labs Report Faster Pay For Molecular, Genetic Tests via New CPT Code Reimbursement Program

DURING RECENT MONTHS, some labs are reporting improvement in how their claims for certain molecular and genetic tests are being reimbursed. This is progress from the financial crises experienced during 2013 for many labs performing molecular and genetic tests. Disruption in these payments was one of the clinical lab industry’s biggest stories during 2013. There

To access this post, you must purchase The Dark Report.

Some Labs Report Faster Pay For Molecular, Genetic Tests via New CPT Code Reimbursement Program Read More »

New Laboratory Industry Trend: Labs Must Prepare for End of Fee-for-Service Model

CEO SUMMARY: One stark difference between the presentations delivered at last year’s Executive War College and this year’s presentations in New Orleans last week was near-unanimous recognition that the era of fee-for-service payment is soon to end! Speaker after speaker urged the audience to accept this marketplace reality in laboratory industry trends. The common recommendation

To access this post, you must purchase The Dark Report.

New Laboratory Industry Trend: Labs Must Prepare for End of Fee-for-Service Model Read More »

;